Jazz Pharmaceuticals Reports Record Revenue in 2025

CFO highlights commercial, pipeline, and corporate advancements that position the company for continued growth in 2026.

Mar. 12, 2026 at 4:12pm

Got story updates? Submit your updates here. ›

Jazz Pharmaceuticals plc, a global biopharmaceutical company, reported record revenue in 2025, driven by strong growth in key products like Xywav, Epidiolex, and Modeyso. The company's CFO, Philip Johnson, discussed the company's commercial, pipeline, and corporate advancements that set Jazz up for continued success in 2026 during a presentation at the Barclays 28th Annual Global Healthcare Conference.

Why it matters

Jazz Pharmaceuticals is a leading specialty pharmaceutical company focused on developing and commercializing innovative therapies for people with serious medical conditions. The company's strong financial performance and pipeline progress are important indicators of its ability to continue delivering value to patients and shareholders.

The details

In 2025, Jazz Pharmaceuticals reported record revenue, growing 5% year-over-year. This was driven by 12% growth in Xywav, 9% growth in Epidiolex, and initial uptake of the company's new product Modeyso. Jazz has now achieved 21 consecutive years of revenue growth, a remarkable accomplishment. The company's CFO highlighted advancements across the commercial, pipeline, and corporate areas that position Jazz for continued success in 2026.

  • Jazz Pharmaceuticals reported its record 2025 results on its recent Q4 earnings call.

The players

Jazz Pharmaceuticals plc

A global biopharmaceutical company focused on developing and commercializing innovative therapies for people with serious medical conditions.

Philip Johnson

Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals.

John Bluth

Head of Investor Relations at Jazz Pharmaceuticals.

Etzer Darout

Senior biotech analyst at Barclays.

Got photos? Submit your photos here. ›

What they’re saying

“2025 was a great year for the company and really sets us up extremely well for 2026.”

— Philip Johnson, Executive VP & CFO

What’s next

Jazz Pharmaceuticals will provide more details on its 2026 outlook and guidance when it reports its full-year 2025 financial results.

The takeaway

Jazz Pharmaceuticals' strong financial performance and pipeline progress demonstrate its ability to continue delivering innovative therapies and value to patients and shareholders in the years ahead.